Erratum: Interferon and Ribavirin Combination Treatment Synergistically Inhibit HCV Internal Ribosome Entry Site Mediated Translation at the Level of Polyribosome Formation (PLoS ONE (2013) 8:8 (e72791) DOI: 10.1371/journal.pone.0072791);Interferon and Ribavirin Combination Treatment Synergistically Inhibit HCV Internal Ribosome Entry Site Mediated Translation at the Level of Polyribosome Formation

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Panigrahi, Rajesh ^a   Hazari, Sidhartha ^a   Chandra, Sruti ^a   Chandra, Partha K ^a   Datta, Sibnarayan ^a   Kurt, Ramazan ^a   Cameron, Craig E ^b   Huang, Zhuhui ^c   Zhang, Haitao ^a   Garry, Robert F ^a   Balart, Luis A ^a   Dash, Srikanta ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

^c SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INITIATION FACTOR 2ALPHA; INOSINATE DEHYDROGENASE; INTERLEUKIN 29; MESSENGER RNA; PROTEIN KINASE R; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME INHIBITION; GENE EXPRESSION; HEPATITIS C; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; INTERNAL RIBOSOME ENTRY SITE; NONHUMAN; POLYSOME; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; VIRUS EXPRESSION; VIRUS REPLICATION;

HEPATITIS C VIRUS;

ANTIVIRAL AGENTS; CELL CULTURE TECHNIQUES; CELL LINE; DRUG SYNERGISM; EIF-2 KINASE; GENE EXPRESSION REGULATION, VIRAL; GENES, REPORTER; GENOME, VIRAL; HEPACIVIRUS; HUMANS; IMP DEHYDROGENASE; INTERFERONS; POLYRIBOSOMES; PROTEIN BINDING; PROTEIN BIOSYNTHESIS; REPLICON; RIBAVIRIN; RNA, MESSENGER; RNA, VIRAL; VIRUS REPLICATION;

EID: 84883024417     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0266498     Document Type: Erratum

References (46)

1. Lavanchy D, (2009) The global burden of hepatitis C. Liver Int 29 (Suppl 1)():: 74-81. doi:10.1111/j.1478-3231.2008.01702.x. PubMed: 19207969.
2. Shepard CW, Finelli L, Alter MJ, (2005) Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5: 558-567. doi:10.1016/S1473-3099(05)70216-4. PubMed: 16122679.
3. Moradpour D, Penin F, Rice CM, (2007) Replication of hepatitis C virus. Nat Rev Microbiol 5(6):: 453-463. doi:10.1038/nrmicro1645. PubMed: 17487147.
4. Qi ZT, Kalkeri G, Hanible J, Prabhu R, Bastian F, et al. (2003) Stem-loop structures (II-IV) of the 5' untranslated sequences are required for the expression of the full-length hepatitis C virus genome. Arch Virol 148[3]:: 449-467. doi:10.1007/s00705-002-0933-0. PubMed: 12607098.
5. Friebe P, Bartenschlager R, (2002) Genetic analysis of the sequences in the 3' UTR of hepatitis C virus that are important for RNA replication. J Virol 76: 5326-5338. doi:10.1128/JVI.76.11.5326-5338.2002. PubMed: 11991961.
6. Blanchard E, Belouzard S, Goueslain L, Wakita T, Dubuisson J, et al. (2006) Hepatitis C virus entry depends on clathrin-mediated endocytosis. J Virol 80: 6964-6972. doi:10.1128/JVI.00024-06. PubMed: 16809302.
7. Hofmann WP, Zeuzem S, (2011) A new standard of care for the treatment of chronic HCV infection. Nat Rev Gastroenterol Hepatol 8: 257-264. PubMed: 21468124.
8. Paeshuyse J, Dallmeier K, Neyts J, (2011) RBV for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action. Curr Opin Virol 1(6):: 590-598. doi:10.1016/j.coviro.2011.10.030. PubMed: 22440916.
9. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, et al. (1998) Interferon alfa-2b alone or in combination with RBV for the treatment of relapse of chronic hepatitis C. N Engl J Med 339: 1493-1499. doi:10.1056/NEJM199811193392102. PubMed: 9819447.
10. Sidwell RW, Witkowsk JT, Allen LB, Robins RK, Khare GP, et al. (1972) Broad-spectrum antiviral activity of virazole-1-beta-d-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science 177: 705-706. doi:10.1126/science.177.4050.705. PubMed: 4340949.
11. Feld JJ, Hoofnagle JH, (2005) Mechanism of action of interferon and RBV in treatment of hepatitis C. Nature 436(7053):: 967-972. doi:10.1038/nature04082. PubMed: 16107837.
12. Hazari S, Chandra PK, Poat B, Datta S, Garry RF, et al. (2010) Impaired antiviral activity of IFN-α in Huh-7 cells with defective Jak-Stat pathway. Virol J 7: 36. doi:10.1186/1743-422X-7-36. PubMed: 20149251.
13. Liu S, Nelson CA, Xiao L, Lu L, Seth PP, et al. (2011) Measuring antiviral activity of benzimidazole molecules that alter IRES RNA structure with an infectious hepatitis C virus chimera expressing Renilla luciferase. Antiviral Res 89: 54-63. doi:10.1016/j.antiviral.2010.11.004. PubMed: 21075143.
14. Aoki Y, Aizaki H, Shimoike T, Tani H, Ishii K, et al. (1998) A human liver cell line exhbits efficient translation of HCV RNA produced by a recombinant adenovirus expressing T7 RNA polymerase. Virology 250: 140-150. doi:10.1006/viro.1998.9361. PubMed: 9770428.
15. Datta S, Hazari S, Chandra PK, Samara M, et al. (2011) Mechanisms of HCV's resistance to IFN-alpha in cell culture involve expression of functional IFN-alpha receptor 1. Virol J 8: 351. doi:10.1186/1743-422X-8-351. PubMed: 21756311.
16. Hazari S, Patil A, Joshi V, Sullivan DE, Fermin CD, et al. (2005) Alpha interferon inhibits translation mediated by the internal ribosome entry site of six different hepatitis C virus genotypes. J Gen Virol 86: 3047-3053. doi:10.1099/vir.0.81132-0. PubMed: 16227227.
17. Chou TC, Talalay PA, (1977) Simple generalized equation for the analysis of multiple inhibitors of Michaelis-Menten kinetic system. J Biol Chem 252: 6438-6442. PubMed: 893418.
18. Chou TC, Talalay P, (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55. doi:10.1016/0065-2571(84)90007-4. PubMed: 6382953.
19. Prichard MN, Aseltine KR, Shipman C Jr, MacSynergy II. Version 1.0 User manual. Ann Arbor: University of Michigan.
20. Prichard MN, Shipman Jr C, (1996) Analysis of combinations of antiviral drugs and design of effective multidrug therapies. Antiviral Therapies 1: 9-20.
21. Taha C, Liu Z, Jin J, AL-Hasani H, Sonenberg N, et al. (1999) Opposite translational control of Glut 1 and Glut 4 glucose transporter mRNA in response to insulin. J Biol Chem 274: 33085-33091. doi:10.1074/jbc.274.46.33085. PubMed: 10551878.
22. Lerner RS, Nicchitta CV, (2006) mRNA translation is compartmentalized to the endoplasmic reticulum following physiological inhibition of cap-dependent translation. RNA 12: 775-789. doi:10.1261/rna.2318906. PubMed: 16540694.
23. Dash S, Shah K, Prabhu R, Deluca C, Bastian F, et al. (2005) IFNα, beta, gamma each inhibits hepatitis C virus replication at the levels of internal ribosome entry site mediated translation. Liver Int 25[3]:: 580-594. doi:10.1111/j.1478-3231.2005.01082.x. PubMed: 15910496.
24. Guo JT, Bichko VV, Seeger C, (2001) Effect of alpha interferon on the hepatitis C virus replicon. J Virol 75: 8516-8523. doi:10.1128/JVI.75.18.8516-8523.2001. PubMed: 11507197.
25. Goodbourn S, Didcock L, Randall RE, (2000) Interferons: cell signaling, immune modulation, antiviral responses and virus countermeasures. J Gen Virol 81: 2341-2364. PubMed: 10993923.
26. Jiang D, Guo H, Xu C, Chang J, Gu B, et al. (2008) Identification of three interferon-inducible cellular enzymes that inhibit the replication of hepatitis C virus. J Virol 82[4]:: 1665-1678. doi:10.1128/JVI.02113-07. PubMed: 18077728.
27. Wang C, Pflugheber J, Sumpter R, Sodora DL, Hui D, et al. (2003) Alpha interferon induces distinct translational control programs to suppress hepatitis C virus RNA replication. J Virol 77: 3898-3912. doi:10.1128/JVI.77.7.3898-3912.2003. PubMed: 12634350.
28. Rivas-Estilla AM, Svitkin Y, Lastra ML, Hatzoglou M, Sherker A, et al. (2002) PKR-dependent mechanisms of gene expression from a subgenomic hepatitis C virus clone. J Virol 76: 10637-10653. doi:10.1128/JVI.76.21.10637-10653.2002. PubMed: 12368306.
29. Shimazaki T, Honda M, Kaneko S, Kobayashi K, (2002) Inhibition of internal ribosomal entry site-directed translation of HCV by recombinant IFN-alpha correlates with a reduced La protein. Hepatology 35: 199-208. doi:10.1053/jhep.2002.30202. PubMed: 11786977.
30. Koev G, Duncan RF, Lai MM, (2002) Hepatitis C virus IRES-dependent translation is insensitive to an eIF2alpha-independent mechanism of inhibition by interferon in hepatocyte cell lines. Virology 297: 195-202. doi:10.1006/viro.2002.1455. PubMed: 12083818.
31. Kato J, Kato N, Moriyama M, Goto T, Taniguchi H, et al. (2002) Interferons specifically suppress the translation from the internal ribosome entry site of hepatitis C virus through a double-stranded RNA- activated protein kinase-independent pathway. J Infect Dis 186: 155-163. doi:10.1086/341467. PubMed: 12134250.
32. Kanda T, Wu S, Kiyohara T, Nakamoto S, Jiang X, et al. (2012) Interleukin-29 suppresses hepatitis A and hepatitis C viral internal ribosome entry site-mediated translation. Viral Immunol 25(5):: 379-386. doi:10.1089/vim.2012.0021. PubMed: 23035851.
33. Dabo S, Meurs EF, (2012) DsRNA-dependent protein kinase PKR and its role in stress, signaling and HCV infection. Viruses 4(11):: 2598-2635. PubMed: 23202496.
34. Leyssen P, Balzarini J, De Clercq E, Neyts J, (2005) The predominant mechanism by which RBV exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J Virol 79: 1943-1947. doi:10.1128/JVI.79.3.1943-1947.2005. PubMed: 15650220.
35. Shu QN, Nair V, (2008) Inosine monophosphate dehydrogenase (IMPDH) as a target in drug discovery. Med Res Rev 28: 219-232. doi:10.1002/med.20104. PubMed: 17480004.
36. Leyssen P, De Clercq E E, J Neyts J (2006) The anti-yellow fever virus activity of RBV is independent of error-prone replication. Mol Pharmacol 69: 1461-1467 doi:10.1124/mol.105.020057. PubMed: 16421290.
37. Mori K, Ikeda M, Ariumi Y, Dansako H, Wakita T, et al. (2011) Mechanism of action of RBV in a novel hepatitis C virus replication cell system. Virus Res 157: 61-70. doi:10.1016/j.virusres.2011.02.005. PubMed: 21320556.
38. Simister P, Schmitt M, Geitmann M, Wicht O, Danielson UH, et al. (2009) Structural and functional analysis of hepatitis C virus strain JFH1 polymerase. J Virol 83: 11926-11939. doi:10.1128/JVI.01008-09. PubMed: 19740982.
39. Zhou S, Liu R, Baroudy BM, Malcolm BA, Reyes GR, (2003) The effect of RBV and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA. Virology 310:: 333-342.
40. Lau JY, Tam RC, Liang TJ, Hong Z, (2002) Mechanism of action of RBV in the combination treatment of chronic HCV infection. Hepatology 35(5):: 1002-1009. doi:10.1053/jhep.2002.32672. PubMed: 11981750.
41. Mortimer SE, Xu D, McGrew D, Hamaguchi N, Lim HC, et al. (2008) IMP dehydrogenise type I associates with polyribosomes translating rhodopsin mRNA. J Biol Chem 283: 36354-36360. doi:10.1074/jbc.M806143200. PubMed: 18974094.
42. Thomas E, Feld JJ, Li Q, Hu Z, Fried MW, et al. (2011) RBV potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. Hepatology 53[1]:: 32-41. doi:10.1002/hep.23985. PubMed: 21254160.
43. Stevenson NJ, Murphy AG, Bourke NM, Keogh CA, Hegarty JE, et al. (2011) RBV enhances IFN-alpha signaling and MxA expression: a novel immune modulation mechanism during treatment of HCV. PLOS ONE 6: e27866. doi:10.1371/journal.pone.0027866. PubMed: 22114715.
44. Liu WL, Su WC, Cheng CW, Hwang LH, Wang CC, et al. (2007) RBV upregulates the activity of double stranded RNA-activated protein kinase and enhances the action of IFNα against HCV virus. J Infect Dis 196: 425-434. doi:10.1086/518894. PubMed: 17597457.
45. Dharel N, Kato N, Muroyama R, Taniquichi H, Otsuka M, et al. (2008) Potential contribution of tumor suppressor p53 in the host defence against hepatitis C virus. Hepatology 47: 1136-1149. PubMed: 18220274.
46. Liu WL, Yang HC, Su WC, Wang CC, Chen HL, et al. (2012) RBV enhances the action of IFNα against hepatitis C virus by promoting the p53 activity through ERK1/2 pathway. PLOS ONE 9: e43824.